RS1 and cyst: In a recently reported AAV2-mediated RS1 gene augmentation trial, clinical response at 12 months was demonstrated only for two endpoints: static perimetry, with two responders of 25 participants, and reduction in cyst cavity volume on SD-OCT, with one responder of 23 participants (23).